Literature DB >> 34887440

Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines.

Heidi Peck1, Karen L Laurie2, Steve Rockman3,4, Vivian Leung5, Hilda Lau5, Sally Soppe5, Cleve Rynehart5, Chantal Baas3, Heidi Trusheim6, Ian G Barr5,4.   

Abstract

Influenza vaccines are utilised to combat seasonal and pandemic influenza. The key to influenza vaccination currently is the availability of candidate vaccine viruses (CVVs). Ideally, CVVs reflect the antigenic characteristics of the circulating virus, which may vary depending upon the isolation method. For traditional inactivated egg-based vaccines, CVVs are isolated in embryonated chicken eggs, while for cell-culture production, CVV's are isolated in either embryonated eggs or qualified cell lines. We compared isolation rates, growth characteristics, genetic stability and antigenicity of cell and egg CVV's derived from the same influenza-positive human clinical respiratory samples collected from 2008-2020. Influenza virus isolation rates in MDCK33016PF cells were twice that of eggs and mutations in the HA protein were common in egg CVVs but rare in cell CVVs. These results indicate that fully cell-based influenza vaccines will improve the choice, match and potentially the effectiveness, of seasonal influenza vaccines compared to egg-based vaccines.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34887440      PMCID: PMC8660794          DOI: 10.1038/s41541-021-00415-3

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  56 in total

1.  The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens.

Authors:  S K Schepetiuk; T Kok
Journal:  J Virol Methods       Date:  1993-05       Impact factor: 2.014

2.  Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans.

Authors:  Weina Sun; Davina S Kang; Allen Zheng; Sean T H Liu; Felix Broecker; Viviana Simon; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

3.  Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility.

Authors:  Nicholas C Wu; Huibin Lv; Andrew J Thompson; Douglas C Wu; Wilson W S Ng; Rameshwar U Kadam; Chih-Wei Lin; Corwin M Nycholat; Ryan McBride; Weiwen Liang; James C Paulson; Chris K P Mok; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2019-05-28       Impact factor: 21.023

4.  Influenza binds phosphorylated glycans from human lung.

Authors:  Lauren Byrd-Leotis; Nan Jia; Sucharita Dutta; Jessica F Trost; Chao Gao; Sandra F Cummings; Thomas Braulke; Sven Müller-Loennies; Jamie Heimburg-Molinaro; David A Steinhauer; Richard D Cummings
Journal:  Sci Adv       Date:  2019-02-13       Impact factor: 14.136

5.  Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses.

Authors:  Bernhard Roth; Hannah Mohr; Martin Enders; Wolfgang Garten; Jens-Peter Gregersen
Journal:  Vaccine       Date:  2011-11-24       Impact factor: 3.641

6.  Species and age related differences in the type and distribution of influenza virus receptors in different tissues of chickens, ducks and turkeys.

Authors:  Smitha P S Pillai; Chang W Lee
Journal:  Virol J       Date:  2010-01-12       Impact factor: 4.099

7.  Influenza Vaccine Effectiveness: Defining the H3N2 Problem.

Authors:  Edward A Belongia; Huong Q McLean
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

8.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

9.  Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine.

Authors:  Sigrid Gouma; Madison Weirick; Scott E Hensley
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919

Review 10.  New Technologies for Influenza Vaccines.

Authors:  Steven Rockman; Karen L Laurie; Simone Parkes; Adam Wheatley; Ian G Barr
Journal:  Microorganisms       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.